Atossa Therapeutics (ATOS) and Quantum Leap Healthcare Collaborative announced the first patient has been dosed in their clinical trial evaluating Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib, a cyclin-dependent kinase 4/6 inhibitor marketed by Eli Lilly (LLY) and Company, as a neoadjuvant treatment in high-risk women with newly diagnosed Estrogen Receptor positive / Human Epidermal Growth Factor Receptor 2 negative breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in oncology with a focus on breast cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
- Texas probes CenterPoint, Carlyle weighs Nobian sale: Monday Buzz
- Texas probes CenterPoint, Starbucks in talks with Elliott: Morning Buzz
- Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Atossa Therapeutics reports Q2 EPS (5c), consensus (6c)